Canada markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
224.92-2.60 (-1.14%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close227.52
Open230.31
Bid223.09 x 800
Ask228.00 x 800
Day's Range223.62 - 230.31
52 Week Range177.05 - 276.69
Volume3,453,588
Avg. Volume2,530,755
Market Cap129.906B
Beta (5Y Monthly)0.73
PE Ratio (TTM)18.27
EPS (TTM)12.31
Earnings DateApr. 28, 2021 - May 03, 2021
Forward Dividend & Yield7.04 (3.13%)
Ex-Dividend DateFeb. 11, 2021
1y Target Est254.24
  • AstraZeneca-Amgen drug could widen treatment options for severe asthma
    Reuters

    AstraZeneca-Amgen drug could widen treatment options for severe asthma

    AstraZeneca and Amgen's experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers. The medicine, tezepelumab, cut the rate of asthma attacks by 56% among patients when compared to placebo in a year-long late-stage study, which had roughly 1,000 patients who were already receiving standard care, the drugmakers said on Friday. It also worked in a subgroup of volunteers with low levels of eosinophils, a type of white blood cell, detailed data presented at a virtual meeting of the American Academy of Allergy Asthma and Immunology showed.

  • Why Turning Point Is Turning Heads
    Motley Fool

    Why Turning Point Is Turning Heads

    This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?

  • Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod
    Zacks

    Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod

    FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.